Primary Objective: To determine if neoadjuvant immunotherapy combined with response-adapted oncologic surgery improves site-reported event-free survival (EFS) compared to standard-of-care surgery in resectable stage III/IV CSCC. Secondary Objectives: To compare disease-free survival (DFS) between arms. To compare overall survival (OS) between arms. To compare adverse events (CTCAE v5.0) between arms. To assess pathologic complete response in Arm 2.
What is the full name of this clinical trial?
NRG-HN014: Randomized Phase III Trial of Neoadjuvant Immunotherapy with Response-adapted Treatment versus Standard of Care Treatment for Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma